![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Moderna Gains Fast-Track Designation for mRNA-Based RSV Vaccine
Moderna Gains Fast-Track Designation for mRNA-Based RSV Vaccine
![Moderna logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Moderna-logo.jpg?t=1589311392&width=430)
The FDA has granted Moderna Fast-Track designation for mRNA-1345, its investigational single-dose mRNA vaccine against respiratory syncytial virus (RSV) in adults older than age 60.
Moderna’s RSV vaccine candidate uses the same lipid nanoparticle as the company’s authorized COVID-19 vaccine and contains optimized protein and nucleotide sequences.
There is currently no approved vaccine for RSV, a common respiratory virus that generally causes cold-like symptoms but can be fatal for elderly adults and young children.
Upcoming Events
-
18Jul
-
21Oct